A pioneer in the immunity design and programming using AI

Adjuvant Systems

Adjuvant systems are critical components of vaccines that enhance immune response and efficacy. We aim to provide reliable supply and open access to advanced adjuvant systems, addressing significant unmet needs in vaccine development and accelerating the availability of these technologies to healthcare providers and patients globally.

ImmunityAI is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use. ImmunityAI’s adjuvants can activate the immune system in specific ways to drive the right immune response to deliver protection against pathogens of interest. Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovering new adjuvants that target STING as well as inflammasome-activating adjuvants. Additionally, our formulations team has extensive expertise in tailoring vaccine delivery systems for these innate immune agonists, to match the route of administration and dosing required for a given indication.

We are actively seeking strategic collaborations to develop and commercialize advanced adjuvant systems for vaccine development. These collaboration leverages our world-class expertise in adjuvant formulation and immunotherapeutics and our partnerss extensive manufacturing and global commercial capabilities.